From: Survey among ESGE members on leiomyosarcoma morcellation incidence
Author and year | Journal | Study | No pts | LMS | LMS risk % |
---|---|---|---|---|---|
Tanos et al. present study [16] | Gyn Surg | Survey | 103,576 | 57 | 0.06 |
Rodriguez et al. 2016 [33] | EJOG-RB | Database analysis | 10,000 | 13 | 0.13 |
< 49 years after myom/my | 0.0012 | ||||
Bojahr et al. 2015 [20] | Gyn Surg | Retrospective | 8724 | 6 | 0.07 |
Pritts et al. 2015 [15] | Gyn Surg | Meta-analysis retrospective studies | 23,926 | 22 | 0.09 |
Pritts et al. 2014 [12] | JMIS | Meta-analysis prospective studies | 5951 | 2 | 0.03 |
Brohl A et al. 2015 (ref. [34]) | The Oncologist | Retrospective 75–79 years | 10,120 | 1.0 | |
< 30 years | < 0.002 | ||||
Wright J et al. 2015 (ref. [35]) | JAMA Oncol | Retrospective 496 hospitals | 3220 | 0.09 | |
Yuk J et al. 2015 (ref. [36]) | Annals SurgOncol | National Korean population | 32,085 Lpic | 0.12–0.07 | |
69,955 Lmy | 0.1–0.05 |